Drugs / Ilaprazole
Ilaprazole
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06725992 | Jan → Apr 2024 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05558150 | Nov → Dec 2022 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02998437 | Dec 2016 → Jan 2017 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01688544 | Jan 2009 → Dec 2011 | — | Inje University | Completed | No outcome recorded |
| Phase 1 | NCT01820143 | Feb → Apr 2005 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT03362268 | Feb → Jun 2014 | peptic ulcer disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01107938 | May → Jun 2010 | gastroesophageal reflux disease | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00471094 | May → Oct 2007 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00953381 | Oct 2004 → Mar 2005 | duodenal ulcer | Livzon Pharmaceutical Group Inc. | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02847455 | Aug 2008 → Oct 2009 | duodenal ulcer | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06284876 | Jul 2024 → Aug 2026 overdue | peptic ulcer disease | Il-Yang Pharm. Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05841394 | Jul 2021 → Apr 2022 | peptic ulcer disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03362281 | Oct 2014 → Apr 2015 | active peptic ulcer disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02084420 | Dec 2012 → Jan 2014 | peptic ulcer disease | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02860624 | Dec 2011 → Apr 2013 | gastroesophageal reflux disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01509261 | Jul 2010 → Jun 2011 | esophagitis, gastroesophageal reflux disease | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00952978 | Sep 2005 → Feb 2006 | duodenal ulcer | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 48 trials · 1 missed | ||||||
| Phase 4 | NCT05624229 | Oct 2023 → Dec 2025 overdue | esophageal varices with bleeding | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03139253 | May → Jun 2017 | — | Yanqing Li | Unknown | No outcome recorded |
| Phase 4 | NCT02648659 | Mar 2016 → Jan 2017 | peptic ulcer disease | Kyungpook National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02638584 | Dec 2015 → Mar 2018 | gastric cancer | Il-Yang Pharm. Co., Ltd. | Completed | Missed primary |
| Phase 4 | NCT02401477 | Dec 2014 → Jun 2015 | Helicobacter pylori infectious disease | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02873065 | Sep 2014 → Jun 2015 | — | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02666976 | Jul 2014 → Aug 2015 | neoplasm | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02835560 | Jun 2013 → Jul 2015 | — | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05455372 | Jul 2022 → Sep 2023 | Helicobacter pylori infectious disease | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT05617651 Comparator | Nov → Dec 2024 | — | Il-Yang Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05509543 Comparator | Aug → Oct 2022 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05237297 Comparator | Feb → Jul 2022 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03444883 Comparator | Oct 2018 → Feb 2020 | gastroesophageal reflux disease | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03342456 Background | Dec 2017 → Jun 2019 | duodenal ulcer | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02988089 Background | Apr → Sep 2017 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT05191875 Background | Dec 2021 → Apr 2022 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| — | NCT05410223 Background | Apr 2021 → Dec 2022 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ilaprazole | “PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.” NCT05455372 ↗33“Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).” NCT02988089 ↗ “Ilaprazole 20mg + Sodium bicarbonate 500mg” NCT06725992 ↗ “Drug: Ilaprazole” NCT05624229 ↗ “Ilaprazole 20mg” NCT05617651 ↗ “Ilaprazole: 5mg” NCT05410223 ↗ “Ilaprazole 20mg” NCT05509543 ↗ |
| Known as | Ilaparazole | “Phase II clinical trials showed that, compared with Esomeprazole, the new PPI Ilaparazole is great in terms of efficacy for reflux symptoms relief and curling for esophagitis.” PMID 29540336 ↗ Mar 2018 |
| Known as | Ilaprazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106370 ↗ |
| Known as | Ilaprazole(Noltec) | “Ilaprazole(Noltec®)” NCT02638584 ↗ |
| Known as | IY-81149 | “To investigate the efficacy and safety of a new proton pump inhibitor (PPI), ilaprazole (IY-81149) in the treatment of duodenal ulcers and provide some characteristics of the...” PMID 20679904 ↗ Apr 2011 |
| Known as | Noltec | “Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days” NCT02401477 ↗ |
| Action | Inhibit | “The new proton pump inhibitor (PPI), ilaprazole performed better at the dose of 10 mg/d relative to 5 or 20 mg/d in a previous phase II trial.” PMID 22070512 ↗ Jan 2012 |
| Modality | Small molecule | “The new proton pump inhibitor (PPI), ilaprazole performed better at the dose of 10 mg/d relative to 5 or 20 mg/d in a previous phase II trial.” PMID 22070512 ↗ Jan 2012 |
| Route | Oral | “Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.” NCT00471094 ↗ |